Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study).
Aihara M, Lu F, Kawata H, Tanaka Y, Yamamura K, Odani-Kawabata N, Shams NK. Aihara M, et al. Among authors: shams nk. J Ocul Pharmacol Ther. 2019 Dec;35(10):542-550. doi: 10.1089/jop.2019.0044. Epub 2019 Nov 1. J Ocul Pharmacol Ther. 2019. PMID: 31674861 Free PMC article. Clinical Trial.
Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys.
Fuwa M, Shimazaki A, Odani-Kawabata N, Kirihara T, Taniguchi T, Iwamura R, Yoneda K, Kato M, Morishima K, Shams NK. Fuwa M, et al. Among authors: shams nk. J Ocul Pharmacol Ther. 2021 May;37(4):223-229. doi: 10.1089/jop.2020.0071. Epub 2021 Feb 17. J Ocul Pharmacol Ther. 2021. PMID: 33600237
127 results